AdAlta Limited (ASX: 1AD) CEO and Managing Director, Dr Tim Oldham presented at the Investor Summit on 1 June, 2023.
The webinar presentation covers how AdAlta, as a clinical stage biotech company is developing a pipeline of next generation therapeutics to treat challenging diseases in fibrosis and oncology. It covers AdAlta’s three partnering streams: 1️⃣ out-licensing AD-214; 2️⃣ partnering the i-body platform; and 3️⃣ evaluating complimentary technologies and products.
On Thursday 25 May, AdAlta’s CEO and Managing Director, Dr Tim Oldham presented at an in-person Twilight Investor briefing in Melbourne along with our collaboration partner, Carina Biotech’s CEO, Dr Deborah Rathjen.
Dr Oldham explained AdAlta’s current areas of strategic focus, including lead program AD-214, our CAR-T cell therapy program and progress on partnering opportunities.
The event was hosted by Peak Asset Management, the corporate advisor for AdAlta’s recent Rights Offer.
To watch a recording of the event (presentation slides and audio), click below.
The presentation slides can also be viewed by CLICKING HERE
AdAlta’s CEO and Managing Director Dr Tim Oldham held a webinar on Wednesday 3 May 2023 to discuss the recently launched A$3.15 million non-renounceable rights offer (Offer) to shareholders. During the webinar, Tim covered AdAlta’s four strategic objectives and various milestones the Company is working towards, including an early return to the clinic for AD-214.
The strategic objectives to create and crystallise value from our i-body platform include:
Realising the value of AD-214, including the generation of new clinical data for partnering
Extending the i-CAR programs
Progressing i-PET development
Investing in the i-bodyTM platform internally and through synergistic technology and product collaborations
To watch a recording of the webcast, please CLICK HERE or on the image below.
Bioshares have recently reported on AdAlta’s strategy update for its lead drug candidate AD-214 and plans for returning AD-214 to clinical studies.
The report covers the background on AdAlta’s 2021 announcement about plans to add an inhaled formulation for AD-214 to the existing intravenous route and the three keys reasons for the decision to prioritise the intravenous formulation for next clinical trials.
This video series covers AdAlta’s 2021 Investor Briefing.
At the briefing, CEO Tim Oldham, VP Clinical Product Development Claudia Gregorio-King and Prof Glen Westall, a leading respiratory and lung fibrosis specialist, discussed the Company’s strategic progress and top-line results from Part A of the Phase I clinical trial of AD-214.
Highlight
Tim Oldham, CEO and Managing Director
AdAlta Investor Briefing March 10, 2021
Adalta (ASX:1AD) Chief Executive Officer & Managing Director, Dr Tim Oldham, talked about the positive progress from AdAlta’s AD-214 Part A of the Phase I trial and how the results.
Investor Update: Tim Oldham, CEO and Managing Director.
Investor Briefing March 10, 2021
Adalta (ASX:1AD) Chief Executive Officer & Managing Director, Dr Tim Oldham, talked about the positive progress from AdAlta’s AD-214 Part A of the Phase I trial and how the results have led to expanded opportunities for the company, the initial clinical validation i-body platform and how it has now also strengthened AdAlta’s asset creation options. Dr Oldham also discussed the significant milestones achieved since March 2020.
AD-214 Phase I HV SAD top-line results
Claudia Gregorio-King, Vice President, Clinical Product Development
AdAlta Investor Briefing March 10, 2021
AdAlta (ASX:1AD) Vice President, Clinical Product Development Claudia Gregorio-King, gave a detailed explanation of the preliminary healthy volunteer single dose results. In the discussion, Claudia explained AD-214’s excellent safety profile, how AD-214 engages the CXCR4 receptor, and how the results showed that receptor occupancy was sustained at high levels for an extended period of time.
Context: importance for IPF
Professor Glen Westall, Leading respiratory and lung fibrosis specialist
AdAlta Investor Briefing March 10, 2021
Leading respiratory and lung fibrosis specialist, Professor Glen Westall, spoke about the global environment for lung fibrosis, the limitations of available treatments and the significance of AdAlta’s recent initial clinical results and AD-214 development approach.
Looking ahead
Tim Oldham, CEO and Managing Director
AdAlta Investor Briefing March 10, 2021
AdAlta’s (ASX:1AD) CEO and Managing Director Tom Oldham discussed AdAlta’s long- and short-term strategic goals, reaffirming benefits of the redesigned Phase I program for AD-214. Dr Oldham also explained how clinical and commercial validation of i-body platform is unlocking new possibilities for pipeline expansion, allowing AdAlta to become a multi-asset company.
As September draws to a close, we’d like to look back on Pulmonary Fibrosis Awareness Month.
While the world has changed immensely in 2020, the need to develop a better treatment for pulmonary fibrosis remains as acute as ever.
In commemoration of the month, we’d like to share this 2017 blog post with Specialist Respiratory and Transplant Physician, Dr Glen Westall.
In the post, Dr Westall discusses Idiopathic Pulmonary Fibrosis (IPF) and his first-hand experience with the disease.
Associate Professor Glen Westall – Specialist Respiratory and Transplant Physician
Associate Professor Glen Westall has worked in the field of lung fibrosis for more than 15 years, published over 70 original research manuscripts and co-authored 8 book chapters in the field of lung fibrosis and lung transplantation.
Yet despite his extensive knowledge about the disease, Idiopathic Pulmonary Fibrosis (IPF) can still surprise him.
“Medical text books suggest that most diseases behave similarly, however the human experience tells us otherwise,” said Assoc. Prof Westall.
“Some patients with IPF can be stable for decades, whilst others often have a very aggressive disease that deteriorates rapidly.”
A highly regarded specialist based at The Alfred, Assoc. Prof. Westall’s interest in lung fibrosis was sparked more than 15 years ago when he worked in London as a registrar in the Royal Brompton Hospital’s Lung Fibrosis service under two giants in the field, Prof Ron du Bois and Prof Athol Wells.
“Back then, we had no treatments for IPF, we were heavily involved with clinical trials, recognising that without treatment, IPF was a progressive and typically fatal condition.
“We are entering an exciting era for lung fibrosis. We now have two antifibrotic agents, Nintedanib and Perfenidone that are available in Australia. More importantly, there are a large number of phase 1 and phase 2 studies running or in the pipeline evaluating new antifibrotic agents”
“Whilst we are making progress, there remains much work that still needs to be done in understanding IPF, both at a patient and a scientific level.”
Our CEO Tim Oldham was recently interviewed by the Australian Shareholders Association about his passion for life sciences and how he came to build his career in the sector, Idiopathic Pulmonary Fibrosis and the clinical development of lead candidate, AD-214
AdAlta Limited (ASX: 1AD) is pleased to announce that Dr Tim Oldham will present at the IRD Invest virtual investor conference on Wednesday, 29 July 2020 at – 11:30 am AEST. Dr Time Oldham will provide an update on the recent developments and future plans at AdAlta.
The event is free to attend and investors are invited to register, ahead of time via the following link:
AdAlta recently achieved a transformational milestone, with ethics approval of our phase I human trial for lead candidate AD-214 marking our successful transition to a clinical stage biotechnology company.
The approval is the first independent review of our complete pre-clinical development package and confirms that we have completed all the necessary safety and efficacy testing to support progressing the development of AD-214 into human clinical studies, a milestone that the AdAlta team has been working towards for many years.
Our CEO Dr Tim Oldham says that ethics approval is a “coming of age moment”, and notes the milestone is important for three reasons.
“It validates the quality of the work we have done to date on AD-214, it proves that we can develop a drug all the way from discovery through to clinical stage, and this study will help validate our entire platform,” he says.
“I’m incredibly proud of this achievement and incredibly grateful to everyone who has been involved on our journey so far and to those who will be involved in our study as we work towards improving outcomes for those patients suffering the debilitating effects of ILD and IPF.”
Our announcement on ethics approval was also featured in online financial news outlet, The Sentiment. You can read the article here.
About the phase I study of AD-214
The first subject in the phase I study is expected to receive AD-214 in the second half of July and top-line safety results from the healthy volunteers are expected to be available at the beginning of CY2021.
Subject to satisfactory completion of Part A of the trial, initiation of Parts B and C of the trial in patients with Interstitial Lung Disease (ILD), including patients with Idiopathic Pulmonary Fibrosis (IPF), is expected early in 2021. The primary end point of the trial is safety and tolerability of AD-214. The trial is not designed to show evidence of efficacy against ILD or IPF.
Our CEO, Dr Tim Oldham discusses the significance of AdAlta becoming a clinical stage company, as well as the aims of the Phase I trial of AD-214, the importance of developing therapies for fibrotic diseases and the significant pharma interest in therapies for Idiopathic Pulmonary Fibrosis.
